Seagen - SGEN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $229.00
Forecasted Upside: 0.11%
Number of Analysts: 2
Breakdown:
0 Sell Ratings
2 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$228.74 As of 01/9/2024 01:00 AM ET

+0 (0.00%)

Get New Seagen Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGEN

^$229.00

▲ +0.11% Upside Potential

This price target is based on 2 analysts offering 12 month price targets for Seagen in the last 3 months. The average price target is $229.00, with a high forecast of $229.00 and a low forecast of $229.00. The average price target represents a 0.11% upside from the last price of $228.74.

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Seagen. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/26/2022

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/24/2023

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/24/2023

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/23/2023

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/21/2023

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/19/2024

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/19/2024

0 strong buy ratings
0 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/18/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/18/2023	Truist Financial	Reiterated Rating	Hold ➝ Hold	$229.00	Low
9/25/2023	Truist Financial	Reiterated Rating	Hold ➝ Hold	$229.00	Low
8/3/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$229.00	Low
4/28/2023	Stifel Nicolaus	Boost Target		$157.00 ➝ $229.00	Low
3/24/2023	Berenberg Bank	Downgrade	Buy ➝ Hold		Low
3/21/2023	TD Securities	Lower Target	Market Perform	$145.00 ➝ $129.00	Low
3/20/2023	Truist Financial	Boost Target		$152.00 ➝ $229.00	Low
3/15/2023	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$173.00 ➝ $229.00	Low
3/14/2023	BMO Capital Markets	Reiterated Rating	Outperform ➝ Market Perform	$179.00 ➝ $229.00	Low
3/14/2023	Royal Bank of Canada	Boost Target	Outperform	$155.00 ➝ $229.00	Low
3/14/2023	SVB Securities	Boost Target		$141.00 ➝ $229.00	Low
3/14/2023	Oppenheimer	Boost Target	Outperform	$210.00 ➝ $229.00	Low
3/14/2023	Barclays	Boost Target	Equal Weight	$145.00 ➝ $228.00	Low
3/14/2023	JMP Securities	Downgrade	Outperform ➝ Market Perform		Low
3/13/2023	Needham & Company LLC	Downgrade	Buy ➝ Hold		Low
3/13/2023	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		Low
3/6/2023	Needham & Company LLC	Boost Target	Buy	$178.00 ➝ $185.00	Low
2/28/2023	Guggenheim	Reiterated Rating	Buy	$170.00	Low
2/28/2023	Oppenheimer	Boost Target	Outperform	$180.00 ➝ $210.00	Low
2/23/2023	Needham & Company LLC	Boost Target	Buy	$160.00 ➝ $178.00	Low
2/17/2023	Oppenheimer	Boost Target	Outperform	$178.00 ➝ $180.00	Low
2/17/2023	Truist Financial	Boost Target		$135.00 ➝ $152.00	Low
2/17/2023	JMP Securities	Boost Target	Market Outperform	$142.00 ➝ $168.00	Low
2/16/2023	HC Wainwright	Reiterated Rating	Buy	$180.00	Low
2/16/2023	Needham & Company LLC	Reiterated Rating	Buy	$160.00	Low
2/16/2023	BMO Capital Markets	Boost Target	Outperform	$177.00 ➝ $179.00	Low
2/16/2023	Morgan Stanley	Boost Target	Overweight	$170.00 ➝ $173.00	Low
2/16/2023	Royal Bank of Canada	Boost Target	Outperform	$145.00 ➝ $155.00	Low
2/16/2023	Evercore ISI	Upgrade	In-Line ➝ Outperform	$140.00 ➝ $175.00	Low
2/16/2023	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$155.00 ➝ $175.00	Low
2/13/2023	JPMorgan Chase & Co.	Lower Target	Overweight	$154.00 ➝ $150.00	Low
2/10/2023	Oppenheimer	Lower Target	Outperform	$188.00 ➝ $178.00	Low
2/6/2023	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$162.00 ➝ $141.00	Low
2/6/2023	SVB Securities	Downgrade	Outperform ➝ Market Perform	$162.00 ➝ $141.00	Low
1/25/2023	Berenberg Bank	Lower Target	Buy	$183.00 ➝ $170.00	Low
1/24/2023	Morgan Stanley	Lower Target	Overweight	$171.00 ➝ $170.00	Low
1/20/2023	SVB Leerink	Boost Target	Outperform	$160.00 ➝ $162.00	Low
11/21/2022	Truist Financial	Initiated Coverage	Hold	$135.00	Low
11/2/2022	JMP Securities	Lower Target	Market Outperform	$196.00 ➝ $142.00	Low
11/1/2022	Guggenheim	Lower Target		$170.00	Low
11/1/2022	Cowen	Lower Target		$145.00	Low
10/28/2022	Raymond James	Lower Target	Outperform	$220.00 ➝ $155.00	Low
10/28/2022	Royal Bank of Canada	Lower Target	Outperform	$185.00 ➝ $178.00	Low
10/28/2022	Barclays	Lower Target	Equal Weight	$174.00 ➝ $136.00	Low
10/28/2022	Morgan Stanley	Boost Target	Overweight	$170.00 ➝ $171.00	Low
10/28/2022	Oppenheimer	Lower Target	Outperform	$208.00 ➝ $188.00	Low
10/28/2022	HC Wainwright	Lower Target	Buy	$200.00 ➝ $180.00	Low
10/24/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$194.00 ➝ $155.00	Low
10/13/2022	Morgan Stanley	Lower Target	Overweight	$181.00 ➝ $170.00	Low
10/11/2022	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$177.00 ➝ $178.00	N/A
9/13/2022	SVB Leerink	Boost Target	Outperform	$152.00 ➝ $160.00	Low
8/15/2022	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$179.00 ➝ $188.00	Low
8/15/2022	SVB Leerink	Lower Target	Outperform ➝ Outperform	$159.00 ➝ $152.00	Low
7/29/2022	Royal Bank of Canada	Boost Target		$136.00 ➝ $179.00	Low
7/29/2022	Morgan Stanley	Boost Target	Overweight	$180.00 ➝ $181.00	Low
7/27/2022	Needham & Company LLC	Boost Target	Buy	$180.00 ➝ $188.00	Low
7/27/2022	HC Wainwright	Boost Target	Buy	$170.00 ➝ $200.00	Low
7/19/2022	Guggenheim	Set Target		$204.00	Low
7/15/2022	Morgan Stanley	Boost Target	Overweight	$173.00 ➝ $180.00	Low
7/8/2022	JMP Securities	Boost Target	Market Outperform	$157.00 ➝ $196.00	N/A
6/29/2022	Raymond James	Initiated Coverage	Outperform	$220.00	Low
6/23/2022	BMO Capital Markets	Initiated Coverage	Market Perform	$169.00	Low
6/21/2022	Oppenheimer	Boost Target	Outperform	$160.00 ➝ $208.00	Low
6/8/2022	JMP Securities	Reiterated Rating	Buy	$157.00	Low
6/6/2022	SVB Leerink	Boost Target	Outperform	$155.00 ➝ $159.00	Low
5/24/2022	JMP Securities	Reiterated Rating	Buy	$157.00	Low
4/18/2022	JMP Securities	Reiterated Rating	Buy	$157.00	Low
4/12/2022	Morgan Stanley	Boost Target	Overweight	$170.00 ➝ $173.00	Medium
2/16/2022	JMP Securities	Lower Target	Market Outperform	$201.00 ➝ $142.00	Low
2/11/2022	Oppenheimer	Lower Target		$198.00 ➝ $162.00	Medium
2/10/2022	Stifel Nicolaus	Lower Target		$180.00 ➝ $145.00	High
2/10/2022	Wolfe Research	Lower Target	Peer Perform	$195.00 ➝ $146.00	High
2/10/2022	Bank of America	Lower Target	Buy	$210.00 ➝ $170.00	High
2/10/2022	Royal Bank of Canada	Lower Target	Sector Perform	$154.00 ➝ $132.00	High
2/10/2022	Morgan Stanley	Lower Target	Overweight	$175.00 ➝ $170.00	High
2/10/2022	SVB Leerink	Lower Target	Outperform	$179.00 ➝ $155.00	High
2/10/2022	HC Wainwright	Lower Target	Buy	$200.00 ➝ $170.00	High
2/10/2022	Piper Sandler	Lower Target	Neutral	$165.00 ➝ $150.00	High
2/7/2022	Needham & Company LLC	Lower Target	Buy	$254.00 ➝ $200.00	High
1/31/2022	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$178.00 ➝ $175.00	High
1/18/2022	Morgan Stanley	Lower Target	Equal Weight	$181.00 ➝ $178.00	Medium
12/14/2021	JMP Securities	Reiterated Rating	Buy	$201.00	Low
11/8/2021	Wolfe Research	Initiated Coverage	Market Perform	$195.00	High
10/29/2021	Morgan Stanley	Boost Target	Equal Weight	$167.00 ➝ $181.00	Low
10/29/2021	Oppenheimer	Boost Target	Outperform	$196.00 ➝ $198.00	High
10/28/2021	Piper Sandler	Boost Target	Neutral	$160.00 ➝ $165.00	High
10/27/2021	SVB Leerink	Boost Target	Outperform	$190.00 ➝ $200.00	Low
9/27/2021	Royal Bank of Canada	Boost Target	Sector Perform	$148.00 ➝ $154.00	Low
9/22/2021	SVB Leerink	Lower Target	Outperform	$192.00 ➝ $190.00	Medium
9/20/2021	Piper Sandler	Reiterated Rating	Hold	$160.00	High
7/16/2021	Morgan Stanley	Lower Target	Equal Weight	$173.00 ➝ $167.00	Medium
5/17/2021	Evercore ISI	Initiated Coverage	Inline	$153.00	Low
4/30/2021	Needham & Company LLC	Initiated Coverage	Buy	$254.00	High
4/30/2021	Piper Sandler	Lower Target	In-Line ➝ Neutral	$170.00 ➝ $160.00	High
3/30/2021	Credit Suisse Group	Initiated Coverage	Neutral	$145.00	Medium
2/16/2021	Royal Bank of Canada	Lower Target	Sector Perform	$186.00 ➝ $169.00	Low
2/12/2021	Morgan Stanley	Lower Target	Equal Weight	$177.00 ➝ $173.00	Low
2/12/2021	SVB Leerink	Lower Target	Outperform	$200.00 ➝ $192.00	Low
2/12/2021	HC Wainwright	Reiterated Rating	Buy		Low
2/12/2021	Berenberg Bank	Reiterated Rating	Buy		Low
2/12/2021	Barclays	Lower Target	Equal Weight	$177.00 ➝ $168.00	Low
2/12/2021	Piper Sandler	Lower Target	In-Line ➝ Neutral	$175.00 ➝ $170.00	Low
2/9/2021	William Blair	Reiterated Rating	Outperform		Low
2/1/2021	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$188.00 ➝ $186.00	Low
1/19/2021	Morgan Stanley	Boost Target	Equal Weight	$175.00 ➝ $177.00	Low
1/15/2021	Bank of America	Upgrade	Neutral ➝ Buy	$215.00	High
11/17/2020	Needham & Company LLC	Reiterated Rating	Buy	$254.00	Medium
10/30/2020	Morgan Stanley	Boost Target	Equal Weight	$167.00 ➝ $175.00	High
10/30/2020	SVB Leerink	Lower Target	Outperform	$204.00 ➝ $200.00	High
10/22/2020	Oppenheimer	Initiated Coverage	Buy	$213.00	Medium
10/16/2020	William Blair	Reiterated Rating	Buy		Medium
10/15/2020	Bank of America	Boost Target	Neutral	$180.00 ➝ $215.00	Low
10/13/2020	JMP Securities	Boost Target	Positive ➝ Outperform	$200.00 ➝ $216.00	Medium
10/12/2020	SVB Leerink	Boost Target	Outperform	$187.00 ➝ $204.00	Medium
9/22/2020	JMP Securities	Boost Target		$185.00 ➝ $200.00	Low
9/22/2020	Stifel Nicolaus	Boost Target	Hold	$145.00 ➝ $165.00	Low
9/22/2020	SVB Leerink	Boost Target	Outperform	$185.00 ➝ $187.00	Low
9/18/2020	Needham & Company LLC	Initiated Coverage	Buy	$188.00	Low
9/16/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
9/15/2020	SVB Leerink	Boost Target	Outperform	$173.00 ➝ $185.00	Medium
9/15/2020	Morgan Stanley	Boost Target	Equal Weight	$160.00 ➝ $167.00	Medium
9/14/2020	Royal Bank of Canada	Boost Target	Outperform	$175.00 ➝ $191.00	Medium
7/31/2020	Morgan Stanley	Boost Target	Equal Weight	$149.00 ➝ $160.00	High
7/31/2020	SVB Leerink	Boost Target	Outperform	$167.00 ➝ $173.00	Low
7/31/2020	HC Wainwright	Reiterated Rating	Buy	$175.00 ➝ $200.00	Low
7/24/2020	Piper Sandler	Downgrade	Overweight ➝ Neutral	$155.00 ➝ $165.00	Low
7/2/2020	William Blair	Reiterated Rating	Buy		Low
6/30/2020	BMO Capital Markets	Boost Target		$174.00 ➝ $186.00	High
6/30/2020	SVB Leerink	Boost Target	Outperform	$155.00 ➝ $167.00	Low
6/30/2020	Needham & Company LLC	Boost Target	Buy	$163.00 ➝ $188.00	Low
6/26/2020	Oppenheimer	Boost Target	Positive ➝ Outperform	$175.00 ➝ $200.00	High
5/31/2020	Oppenheimer	Initiated Coverage	Buy	$146.00 ➝ $175.00	Medium
5/26/2020	JMP Securities	Initiated Coverage	Outperform	$185.00	High
5/26/2020	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		High
5/4/2020	Morgan Stanley	Boost Target	Equal Weight	$111.00 ➝ $149.00	High
5/3/2020	Barclays	Reiterated Rating	Neutral ➝ Hold		High
5/1/2020	Cfra	Boost Target	Sell	$122.00 ➝ $129.00	High
5/1/2020	Stifel Nicolaus	Boost Target	Hold	$120.00 ➝ $127.00	High
5/1/2020	Royal Bank of Canada	Boost Target	Outperform	$148.00 ➝ $149.00	High
5/1/2020	SVB Leerink	Boost Target	Outperform	$146.00 ➝ $155.00	High
5/1/2020	Needham & Company LLC	Boost Target	Buy	$157.00 ➝ $163.00	High
5/1/2020	HC Wainwright	Boost Target	Buy	$150.00 ➝ $175.00	High
5/1/2020	Guggenheim	Upgrade	Neutral ➝ Buy		High
4/27/2020	Piper Sandler	Boost Target	Overweight	$135.00 ➝ $155.00	Low
4/20/2020	BMO Capital Markets	Boost Target	Outperform	$139.00 ➝ $154.00	Medium
4/20/2020	SVB Leerink	Boost Target	Outperform	$138.00 ➝ $146.00	Low
4/20/2020	Stifel Nicolaus	Boost Target	Hold	$103.00 ➝ $120.00	Medium
4/20/2020	Oppenheimer	Boost Target	Outperform	$124.00 ➝ $146.00	Low
4/20/2020	Needham & Company LLC	Boost Target	Positive ➝ Buy	$144.00 ➝ $157.00	Medium
4/20/2020	Royal Bank of Canada	Boost Target	Outperform	$121.00 ➝ $147.00	High
4/20/2020	Piper Sandler	Boost Target	Overweight	$125.00 ➝ $135.00	High
4/19/2020	Royal Bank of Canada	Reiterated Rating	Buy		High
4/15/2020	Morgan Stanley	Boost Target	Equal Weight	$107.00 ➝ $111.00	Medium
4/3/2020	William Blair	Reiterated Rating	Buy		Low
3/3/2020	William Blair	Reiterated Rating	Outperform		Medium
2/18/2020	Barclays	Downgrade	Overweight ➝ Equal Weight	$124.00	Medium
2/12/2020	HC Wainwright	Reiterated Rating	Buy	$140.00 ➝ $150.00	Low
2/11/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
2/11/2020	The Goldman Sachs Group	Boost Target	Buy	$126.00 ➝ $165.00	Low
2/7/2020	Piper Sandler	Lower Target		$125.00	Low
2/7/2020	William Blair	Reiterated Rating	Outperform		High
2/7/2020	Needham & Company LLC	Reiterated Rating	Buy	$135.00	High
1/27/2020	BMO Capital Markets	Initiated Coverage	Outperform	$139.00	Medium
1/27/2020	Royal Bank of Canada	Reiterated Rating	Buy	$113.00	Medium
1/17/2020	Morgan Stanley	Lower Target	Equal Weight	$123.00 ➝ $115.00	Low
1/2/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High
12/22/2019	Cowen	Reiterated Rating	Hold	$100.00	Medium
12/20/2019	Piper Sandler Companies	Boost Target	Overweight	$120.00 ➝ $130.00	High
12/19/2019	William Blair	Reiterated Rating	Buy		Medium
12/19/2019	Stifel Nicolaus	Boost Target		$87.00 ➝ $101.00	High
12/13/2019	William Blair	Reiterated Rating	Buy		Low
12/13/2019	HC Wainwright	Reiterated Rating	Buy	$140.00	Medium
12/12/2019	Oppenheimer	Boost Target	Outperform	$110.00 ➝ $124.00	Low
12/12/2019	Needham & Company LLC	Reiterated Rating	Buy	$130.00	High
12/10/2019	Morgan Stanley	Initiated Coverage	Equal ➝ Equal Weight	$123.00	Low
12/3/2019	Bank of America	Initiated Coverage	Neutral	$125.00	High
10/31/2019	Barclays	Reiterated Rating	Buy	$117.00	Low
10/30/2019	Piper Sandler Companies	Boost Target	Overweight	$120.00	Medium
10/25/2019	William Blair	Reiterated Rating	Buy		Low
10/22/2019	Royal Bank of Canada	Boost Target	Outperform	$80.00 ➝ $109.00	Low
10/22/2019	Deutsche Bank Aktiengesellschaft	Boost Target	Hold	$88.00 ➝ $95.00	Low
10/22/2019	SVB Leerink	Boost Target	Outperform ➝ Positive	$102.00 ➝ $120.00	Medium
10/22/2019	Oppenheimer	Boost Target	Outperform	$92.00 ➝ $110.00	Medium
10/22/2019	Guggenheim	Boost Target	Buy ➝ Outperform	$95.00 ➝ $120.00	Low
10/22/2019	Bank of America	Boost Target	Underperform	$58.00 ➝ $83.00	Low
10/22/2019	HC Wainwright	Reiterated Rating	Buy	$98.00 ➝ $140.00	Medium
10/21/2019	Piper Sandler Companies	Set Target	Buy	$95.00	Low
10/21/2019	Needham & Company LLC	Set Target	Buy	$121.00	Low
10/21/2019	Cowen	Set Target	Hold	$80.00	Low
10/21/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
10/2/2019	Deutsche Bank Aktiengesellschaft	Boost Target	Hold	$79.00 ➝ $88.00	Low
10/1/2019	Oppenheimer	Boost Target	Outperform	$82.00 ➝ $92.00	Low
9/30/2019	Needham & Company LLC	Set Target	Buy	$81.00	Low
9/30/2019	Stifel Nicolaus	Set Target	Hold	$74.00	Low
9/30/2019	SVB Leerink	Set Target	Buy	$102.00	Low
9/30/2019	Cowen	Set Target	Hold	$80.00	High
9/29/2019	Piper Sandler Companies	Boost Target	Overweight	$75.00 ➝ $95.00	High
9/27/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
9/27/2019	Bank of America	Set Target	Sell	$58.00	Low
9/27/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$78.00 ➝ $100.00	High
9/12/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$77.00 ➝ $82.00	Medium
8/26/2019	BTIG Research	Initiated Coverage	Neutral		Low
7/19/2019	William Blair	Reiterated Rating	Buy		Low
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold ➝ Hold	$79.00	Medium
7/17/2019	Piper Sandler Companies	Upgrade	Neutral ➝ Overweight	$64.00 ➝ $75.00	High
6/5/2019	William Blair	Reiterated Rating	Buy		Low
4/28/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
4/26/2019	HC Wainwright	Reiterated Rating	Buy		Medium

(Data available from 4/19/2019 forward)

News Sentiment Rating

0.50 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

15 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/22/2023

20 very positive mentions
11 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

10/22/2023

5 very positive mentions
13 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

11/21/2023

19 very positive mentions
13 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

12/21/2023

4 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

0 very positive mentions
2 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

2/19/2024

0 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/20/2024

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

wsj.com
4/13/2024
Two Brothers, a Big Biotech Bet and an $8 Billion Payout
msn.com
3/20/2024
Ron Baron Portfolio Magic: Building Your Financial Future

Very Positive

No very positive mentions tracked during this time.

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $228.74

$228.74

50 Day Range

MA: $228.74

$228.74

52 Week Range

Now: $228.74

$123.77

$228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Seagen?: The following sell-side analysts have issued reports on Seagen in the last year: Morgan Stanley, Stifel Nicolaus, StockNews.com, TheStreet, and Truist Financial Co..
View the latest analyst ratings for SGEN.
What is the current price target for Seagen?: 3 Wall Street analysts have set twelve-month price targets for Seagen in the last year. Their average twelve-month price target is $229.00, suggesting a possible upside of 0.1%. Stifel Nicolaus has the highest price target set, predicting SGEN will reach $229.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $229.00 for Seagen in the next year.
View the latest price targets for SGEN.
What is the current consensus analyst rating for Seagen?: Seagen currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SGEN, but not buy more shares or sell existing shares.
View the latest ratings for SGEN.
What other companies compete with Seagen?: Other companies that are similar to Seagen include Takeda Pharmaceutical, IQVIA, IDEXX Laboratories, Moderna and Alcon. Learn More about companies similar to Seagen.
How do I contact Seagen's investor relations team?: Seagen's physical mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company's listed phone number is (425) 527-4000 and its investor relations email address is [email protected]. The official website for Seagen is www.seattlegenetics.com. Learn More about contacing Seagen investor relations.

Seagen - SGEN Stock Price Target and Predictions

Analyst Price Target for SGEN

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.50 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Seagen?

What is the current price target for Seagen?

What is the current consensus analyst rating for Seagen?

What other companies compete with Seagen?

How do I contact Seagen's investor relations team?